Serum carbonic anhydrase III in progressive muscular dystrophy

Area of Science:

• Biochemistry
• Clinical Chemistry
• Neuromuscular Disorders

Background:

• Progressive muscular dystrophies (PMD) encompass a group of inherited muscle-weakening diseases.
• Accurate diagnosis and monitoring of muscle disease progression are crucial for patient management.
• Biomarkers for muscle damage and disease activity are essential in clinical practice.

Purpose of the Study:

• To investigate serum carbonic anhydrase III (CA-III) levels in patients with four types of progressive muscular dystrophy (PMD).
• To compare CA-III levels with established muscle enzyme markers, creatine kinase (CK) and muscle-specific enolase (MSE).
• To evaluate the potential of serum CA-III as a diagnostic marker for muscle diseases.

Main Methods:

• Serum samples were collected from 143 patients diagnosed with Duchenne muscular dystrophy (DMD), limb-girdle dystrophy, facioscapulohumeral dystrophy, or congenital dystrophy.
• Serum CA-III levels were quantified using an enzyme immunoassay method.
• Serum CK and MSE levels were also measured and compared with CA-III levels.

Main Results:

• Elevated serum CA-III levels were observed in the majority of PMD patients, with particularly high levels noted in those with DMD.
• A decline in serum CA-III levels with increasing age was observed in DMD patients.
• Strong positive correlations were found between serum CA-III, CK, and MSE levels across all PMD types.
• The frequency of elevated CA-III levels was comparable to or exceeded that of elevated CK or MSE levels.

Conclusions:

• Serum CA-III is frequently elevated in patients with various types of progressive muscular dystrophy.
• Serum CA-III demonstrates a strong correlation with other established muscle damage markers (CK and MSE).
• These findings support the potential utility of serum CA-III as a sensitive and valuable biomarker for diagnosing and monitoring muscle diseases.